Autonomix Medical announces presentations at TCT 2025 showcasing initial results of a clinical study on nerve-targeted pain relief.
Quiver AI Summary
Autonomix Medical, Inc. announced that it will present findings from its first-in-human clinical study at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference in San Francisco, from October 25-28, 2025. The focus of the presentations is on the safety and effectiveness of transvascular energy delivery to target nerves and alleviate pain in pancreatic cancer patients. Two specific sessions will be led by Dr. Robert S. Schwartz on October 27, covering topics related to nerve-targeted technology and pain mitigation strategies. Autonomix's innovative platform aims to transform the diagnosis and treatment of diseases affecting the nervous system, initially targeting pain management in pancreatic cancer. The company's technology is still investigational and not yet approved for U.S. marketing.
Potential Positives
- Autonomix Medical, Inc. will present positive initial results from its first-in-human clinical study at a prestigious annual scientific conference, TCT 2025, elevating its visibility in the medical community.
- The company’s innovative technology focuses on a significant unmet medical need in treating pancreatic cancer pain, potentially positioning it as a leader in addressing chronic pain management.
- Featuring multiple presentations by a recognized expert, Dr. Robert S. Schwartz, underscores the credibility and scientific rigor behind Autonomix's research and innovation.
- The cutting-edge catheter-based microchip sensing technology may revolutionize treatment and diagnosis of diseases affecting the nervous system, promising broad future applications beyond current clinical trials.
Potential Negatives
- The technology is described as investigational and has not yet been cleared for marketing in the United States, indicating a lack of regulatory approval and potential hurdles to commercialization.
- The press release includes numerous "forward-looking statements" that highlight risks and uncertainties associated with the company's future projections, which could lead to investor skepticism.
- The focus on a challenging condition like pancreatic cancer, which currently lacks reliable treatment options, may raise concerns about the feasibility and market potential of the company's solutions.
FAQ
What is the focus of Autonomix Medical?
Autonomix Medical is dedicated to advancing precision nerve-targeted treatments for diseases involving the nervous system.
When will Autonomix present at TCT 2025?
Autonomix will present on October 27, 2025, during the TCT 2025 conference in San Francisco.
What topics will be discussed in Autonomix's presentations?
The presentations will cover transvascular energy delivery for nerve ablation and pain mitigation in pancreatic cancer patients.
Where will the presentations take place?
The sessions will be held at the Moscone Center, specifically in the Innovation Theater and Station 5.
Is Autonomix's technology currently available in the market?
No, Autonomix's technology is investigational and has not yet received market clearance in the United States.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMIX Analyst Ratings
Wall Street analysts have issued reports on $AMIX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 04/29/2025
To track analyst ratings and price targets for $AMIX, check out Quiver Quantitative's $AMIX forecast page.
Full Release
THE WOODLANDS, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics ® (TCT ® ) Annual Scientific Conference (TCT 2025) being held October 25-28, 2025 in San Francisco, CA.
The presentations will highlight positive results from the initial phase of Autonomix’s first-in-human proof-of-concept clinical study evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
Details of the presentations are as follows:
Title:
Illuminating the Nervous System with Transvascular Precision-Guided Technology
Session:
Innovation Session 7: Percutaneous Denervation for the Treatment of Chronic Diseases
Presenter:
Robert S. Schwartz, MD, FACC
Date and Time:
Monday, October 27, at 7:30 AM PDT
Location:
Innovation Theater, Hall E, Exhibition Level, Moscone North
Title:
Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation
Session:
Hypertension and Renal (and other organ system) Denervation - 2
Presenter:
Robert S. Schwartz, MD, FACC
Date and Time:
Monday, October 27, at 9:00 AM PDT
Location:
Station 5, Halls B-C, Exhibition Level, Moscone South
For more information about TCT 2025, visit the conference website here .
About TCT 2025
TCT 2025 is a comprehensive 4-day educational conference, sponsored by the Cardiovascular Research Foundation (CRF), taking place October 25-28, 2025, at the Moscone Center in San Francisco, California. Founded by Dr. Martin B. Leon, the Transcatheter Cardiovascular Therapeutics ® (TCT ® ) conference is the annual scientific symposium of the Cardiovascular Research Foundation ® (CRF ® ) and the world’s foremost educational forum specializing in interventional cardiovascular medicine. Debuting as a small gathering of 150 in 1988, TCT ® now attracts thousands of attendees from around the world. Every year, TCT ® features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit
autonomix.com
and connect with the Company on
X
,
LinkedIn
,
Instagram
and
Facebook
.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
